Paola Cappello

2001-2006 Post-Doctoral Research Scientist, Dept of Clinical and Biological Sciences, University of Turin;
2007-2011 Post-Doctoral Fellowship, Dept of Medicine and Experimental Oncology, University of Turin
2010-2011 Post-Doctoral Research Scientist, Campbell Family Institute for Breast Cancer Research, University Health Network, Toronto (ON, Canada)
2012-today Over this time she has served as an Advisory Committee member for 18 Graduate Students, as 1st opponent on 3 PhD dissertations, University of Turin, Dept. Molecular Biotechnology and Healthy Sciences, Italy
2011-2019 Assistant Professor, Dept of Molecular Biotechnology and Health Sciences, University of Turin
2015-today Member of Molecular Biotechnology Centre, University of Turin
2017 External reviewer of two PhD theses for the admission to the defense: University of Verona and University of Milan, PhD Program in Experimental Medicine and Medical Biotechnologies
2018-present Member of the Department Board, Dept. Molecular Biotechnology and Health Sciences, University of Turin, Italy
2019-2024 Associate Professor, Dept of Molecular Biotechnology and Health Sciences, University of Turin
2020-2024 Deputy Director of the PhD program in Molecular Medicine at the University of Turin

2010-2011 Dr Cappello spent 18 months at the University Health Network, lab of Prof Tak W. Mak Toronto (Canada) at the Campbell Family Institute for Breast Cancer Research as post-doctoral scientist research working on the kinome and its implication in breast cancer metastasization. She went back in the University Health Network, lab of Prof Tak W. Mak Toronto (Canada) several times for weeks, as visiting professor to perform and discuss experimental results in collaboration.

Education

2020: CRT Foundation (RF= 2020.0719): “Characterization of a new immunological target for the development of inhibitors to be used in the treatment of pancreatic cancer” Euro 35000 (two years)
2022: Italian Association for Cancer Research (AIRC)(IG 26341): “Harnessing IL17 family to trigger pancreatic cancer microenvironment and improve immunotherapy” Euro 503000 (fve years)
2022: Fondazione Compagnia di San Paolo (ID 116390), Italy: “ENO3PEP: il vaccino di nuova generazione per la cura del tumore del pancreas, a un passo dalla clinica” Euro 50000 (six months)
2023: MAECI Italy-Singapore in collaboration with Singapore Immunology Network: “Development of a three-dimensional in vitro pancreatic tumor model to study the microenvironment and design more effective immunotherapies”, 300000 (three years)
2023: Progetti di Rilevante Interesse Nazionale (PRIN), Ministero dell’Università e della Ricerca, co-PI: “Unraveling novel microenvironment-induced mechanisms in the pathogenesis of pancreatic intraductal papillary mucinous neoplasms“ Euro 59845 (two years).

1997: Awarded of one of 2 fellowships for Research in Neuroscience, Cavalieri Ottolenghi Foundation, Italy;
1999: European Cytokine Society Student Award (1st Prize);
2004: “Honorary fellow of Immunology”;
2007-2009: Awarded of one of the 40 FIRC-Fellowships, Associazione Italiana per la Ricerca sul Cancro (AIRC), Italy;
2016: National Habilitation as Associate professor of General Pathology(MED/04);
2021: Awarded of the prize entitled “Talent Women” 2nd Edition from the Cenacolo della Scienza e della Cultura, Locri, Italy;
2022: Awarded of the prize entitled “Amelia Earhart 2022: donne che volano nella medicina” from Interclub Zonta, Cuneo, Italy;
2022: National Habilitation as Full professor of General Pathology(MED/04).

Ribovax Biotechnologies, SA (CH), Bioline Diagnostici srl (IT). Novelli F, Tomaino B, Cappello P. Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma. WO/2008/037792A1;
NatiMab Therapeutics srl, F. Novelli, B.Tomaino, P. Cappello. A HUMAN Alpha-enolase derived-monophosphorylated peptide useful for diagnosis and treatment of pancreatic adenocarcinoma and for generate antibodies to the above mentioned mophosphorylarted peptide and their uses; WO2011030302;
NatiMab Therapeutics srl, F. Novelli, M. Capello, P. Cappello. A method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma WO 2013186748 A1.
University of Turin, Italy; F. Novelli, P. Cappello, C. Curcio, S. Brugiapaglia. A DNA vaccine for use in the therapeutic and /or prophylactic treatment of tumor diseases; PCT E141583

Ultimo aggiornamento: 19/11/2024